| Autor: |
Cavalli SA; Department of Clinical and Toxicological Analysis, Faculty of Pharmaceutical Sciences, Sao Paulo University, Sao Paulo, Brazil. scavalli@ups.br, Hirata MH, Hirata RD |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of clinical laboratory analysis [J Clin Lab Anal] 2001; Vol. 15 (1), pp. 35-9. |
| DOI: |
10.1002/1098-2825(2001)15:1<35::aid-jcla7>3.0.co;2-p |
| Abstrakt: |
Several environmental and genetic factors are associated with high levels of cholesterol. Hypercholesterolemia is the main phenotype of Familial Defective Apolipoprotein B and Familial Hypercholesterolemia that are caused by mutations at the apolipoprotein (apo) B and LDL receptor genes, respectively. Identification of the specific genetic alteration associated with hypercholesterolemia is an important issue in clinical diagnosis of high risk for CAD. Apo B gene mutations and polymorphisms are usually screened by SSCP, DGGE, and heteroduplex, which must be confirmed by DNA sequencing or by direct detection using PCR techniques. In this study, we have optimized a PCR-RFLP procedure for identification of 3500Q and 3531 mutations and MspI polymorphism at the apo B gene. The technique can be performed in a single reaction, using the restriction endonuclease MspI for simultaneous detection of 3500Q mutation and MspI polymorphism, and NsiI for detection of 3531 mutation. The procedure was validated by analysis of control DNA samples from individuals carrying these mutations. Screening of 186 Brazilian hypercholesterolemic individuals showed that the frequency of the M-allele (7.8%) of MspI polymorphism was similar to that found in other individuals with CAD. However, neither 3500Q nor 3531 mutations were detected in this group. In conclusion, this procedure is simple and rapid, being easily introduced in clinical laboratories for direct detection of the more frequent mutations at the apo B gene associated with hypercholesterolemia. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
